We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.

learn more


U.S. CDC Highlights High Unmet Cardiovascular Need

A new report published by the U.S. Centers for Disease Control and Prevention (CDC) sheds light on an issue that… more

Posted by Andrew Jillions

Investor Day and July Meetings Recap

Hi, I’m Alex Schwartz and I recently joined Esperion as Head of Investor Relations.  Prior to joining Esperion, I was… more

Posted by mlowe@esperion.com

A Closer Look – June 2018

As we approach the halfway point in 2018, our Lipid Management Team remains confident and encouraged by the consistently positive… more

Posted by mlowe@esperion.com